Literature DB >> 17036249

[The side effects of antiretroviral therapy].

M Hartmann1.   

Abstract

The introduction of highly active antiretroviral therapy (HAART) has resulted in tremendous improvements in morbidity and mortality in HIV-infected patients. However, the use of these drugs has coincided with an increasing number of reports of gastrointestinal, hepatic or metabolic side effects. Soon after beginning antiretroviral treatment drug rashes, hypersensitivity reactions, immune reconstitution syndrome or injection site reaction are frequently seen. Under HAART dyslipidemia, impaired glucose metabolism and elevated liver function are observed. In the later treatment phase, lipodystrophy, a combination of peripheral lipoatrophy and central fat accumulation, occurs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17036249     DOI: 10.1007/s00105-006-1240-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  30 in total

1.  Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.

Authors:  Don E Smith; Sarangapany Jeganathan; John Ray
Journal:  HIV Clin Trials       Date:  2006 Jan-Feb

2.  [Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz].

Authors:  M Hartmann; J Brust; D Schuster; F Mosthaf; M Procaccianti; J A Rump; H Klinker; D Petzoldt
Journal:  Hautarzt       Date:  2005-09       Impact factor: 0.751

3.  An objective case definition of lipodystrophy in HIV-infected adults: a case-control study.

Authors:  A Carr; S Emery; M Law; R Puls; J D Lundgren; W G Powderly
Journal:  Lancet       Date:  2003-03-01       Impact factor: 79.321

Review 4.  Peripheral neuropathy and antiretroviral drugs.

Authors:  M C Dalakas
Journal:  J Peripher Nerv Syst       Date:  2001-03       Impact factor: 3.494

Review 5.  Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

Authors:  Morris Schambelan; Constance A Benson; Andrew Carr; Judith S Currier; Michael P Dubé; John G Gerber; Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Kathleen Mulligan; William G Powderly; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2002-11-01       Impact factor: 3.731

6.  Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors:  J P Fagot; M Mockenhaupt; J N Bouwes-Bavinck; L Naldi; C Viboud; J C Roujeau
Journal:  AIDS       Date:  2001-09-28       Impact factor: 4.177

7.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

Authors:  G Behrens; A Dejam; H Schmidt; H J Balks; G Brabant; T Körner; M Stoll; R E Schmidt
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

8.  Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.

Authors:  Annalise M Martin; David Nolan; Ian James; Paul Cameron; Jean Keller; Corey Moore; Elizabeth Phillips; Frank T Christiansen; Simon Mallal
Journal:  AIDS       Date:  2005-01-03       Impact factor: 4.177

9.  Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.

Authors:  Russell A Ball; Tosca Kinchelow
Journal:  J Am Acad Dermatol       Date:  2003-11       Impact factor: 11.527

Review 10.  Severe cutaneous reactions associated with the use of human immunodeficiency virus medications.

Authors:  Adam Rotunda; Ranella J Hirsch; Noah Scheinfeld; Jeffrey M Weinberg
Journal:  Acta Derm Venereol       Date:  2003       Impact factor: 4.437

View more
  1 in total

1.  Magnitude of Antiretroviral Drug Toxicity in Adult HIV Patients in Ethiopia: A cohort study at seven teaching hospitals.

Authors:  Esayas Kebede Gudina; Alula M Teklu; Asres Berhan; Atsbeha Gebreegziabhier; Teshome Seyoum; Abiy Nega; Girmay Medhin; Amha Kebede; Yibeltal Assefa
Journal:  Ethiop J Health Sci       Date:  2017-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.